Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia

Biomedicine and Pharmacotherapy

Volumn 84, Issue , 2016, Pages 1510-1512

  Allegra, Sarah ^a   De Francia, Silvia ^b   Longo, Filomena ^b   Massano, Davide ^b   Cusato, Jessica ^a   Arduino, Arianna ^a   Pirro, Elisa ^b   Piga, Antonio ^b   D'Avolio, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Deferasirox; Dfx; Haemochromatosis; Ileostomy; Iron chelation; Iron overload

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; DEFERASIROX; FERRITIN; TRANSFERRIN; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BETA THALASSEMIA; CASE REPORT; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG WITHDRAWAL; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; GENE MUTATION; GENETIC BACKGROUND; GENETIC DISORDER; HEMOCHROMATOSIS; HETEROZYGOTE; HIP PROSTHESIS; HUMAN; ILEOSTOMY; ILEUM RESECTION; IRON CHELATION; MAXIMUM PLASMA CONCENTRATION; MEDICAL HISTORY; MIDDLE AGED; MINIMUM PLASMA CONCENTRATION; PARENTERAL NUTRITION; PEAK-TROUGH FLUCTUATION; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; TRANSFERRIN BLOOD LEVEL; VOLUME OF DISTRIBUTION; BETA-THALASSEMIA; BLOOD;

BENZOATES; BETA-THALASSEMIA; FEMALE; HEMOCHROMATOSIS; HUMANS; IRON CHELATING AGENTS; MIDDLE AGED; TRIAZOLES;

EID: 85001104630     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.11.041     Document Type: Article

References (20)

1. [1] Martins, R., Picanco, I., Fonseca, A., Ferreira, L., Rodrigues, O., Coelho, M., Seixas, T., Miranda, A., Nunes, B., Costa, L., Romao, L., Faustino, P., The role of HFE mutations on iron metabolism in beta-thalassemia carriers. J. Hum. Genet. 49:12 (2004), 651–655.
2. [2] Pietrangelo, A., Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 139:2 (2010), 393–408 (408 e1-2).
3. [3] EEPAR, Exjade (deferasirox) Prescribing Information. 2007, Novartis Pharmaceuticals Corporation.
4. [4] Nick, H., Acklin, P., Lattmann, R., Buehlmayer, P., Hauffe, S., Schupp, J., Alberti, D., Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr. Med. Chem. 10:12 (2003), 1065–1076.
5. [5] Nick, H., Wong, A., Acklin, P., Faller, B., Jin, Y., Lattmann, R., Sergejew, T., Hauffe, S., Thomas, H., Schnebli, H.P., ICL670A: preclinical profile. Adv. Exp. Med. Biol. 509 (2002), 185–203.
6. [6] Waldmeier, F., Bruin, G.J., Glaenzel, U., Hazell, K., Sechaud, R., Warrington, S., Porter, J.B., Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metab. Dispos. 38:5 (2010), 808–816.
7. [7] Bruin, G.J., Faller, T., Wiegand, H., Schweitzer, A., Nick, H., Schneider, J., Boernsen, K.O., Waldmeier, F., Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Drug Metab. Dispos. 36:12 (2008), 2523–2538.
8. [8] Galanello, R., Origa, R., Once-daily oral deferasirox for the treatment of transfusional iron overload. Expert Rev. Clin. Pharmacol. 1:2 (2008), 231–240.
9. [9] Cappellini, M.D., Bejaoui, M., Agaoglu, L., Porter, J., Coates, T., Jeng, M., Lai, M.E., Mangiagli, A., Strauss, G., Girot, R., Watman, N., Ferster, A., Loggetto, S., Abish, S., Cario, H., Zoumbos, N., Vichinsky, E., Opitz, H., Ressayre-Djaffer, C., Abetz, L., Rofail, D., Baladi, J.F., Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin. Ther. 29:5 (2007), 909–917.
10. [10] Galanello, R., Piga, A., Alberti, D., Rouan, M.C., Bigler, H., Sechaud, R., Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J. Clin. Pharmacol. 43:6 (2003), 565–572.
11. [11] Nisbet-Brown, E., Olivieri, N.F., Giardina, P.J., Grady, R.W., Neufeld, E.J., Sechaud, R., Krebs-Brown, A.J., Anderson, J.R., Alberti, D., Sizer, K.C., Nathan, D.G., Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 361:9369 (2003), 1597–1602.
12. [12] Cusato, J., Tomasello, C., Simiele, M., Calcagno, A., Bonora, S., Marinaro, L., Leggieri, A., Allegra, S., Di Perri, G., D'Avolio, A., Efavirenz pharmacogenetics in a cohort of Italian patients. Int. J. Antimicrob. Agents 47:2 (2016), 117–123.
13. [13] Cusato, J., Allegra, S., Massano, D., De Francia, S., Piga, A., D'Avolio, A., Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. Pharmacogenomics J. 15:3 (2014), 263–271.
14. [14] Allegra, S., Cusato, J., De Francia, S., Pirro, E., Massano, D., Piga, A., D'Avolio, A., Deferasirox pharmacokinetic evaluation in beta-thalassaemia paediatric patients. J. Pharm. Pharmacol., 2016, 10.1111/jphp.12559 [Epub ahead of print].
15. [15] Allegra, S., Cusato, J., De Francia, S., Massano, D., Piga, A., D'Avolio, A., Deferasirox AUC efficacy cutoff and role of pharmacogenetics. Eur. J. Clin. Pharmacol. 72:9 (2016), 1155–1157.
16. [16] De Francia, S., Massano, D., Piccione, F.M., Pirro, E., Racca, S., Di Carlo, F., Piga, A., A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 893–894 (2012), 127–133.
17. [17] Chirnomas, D., Smith, A.L., Braunstein, J., Finkelstein, Y., Pereira, L., Bergmann, A.K., Grant, F.D., Paley, C., Shannon, M., Neufeld, E.J., Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 114:19 (2009), 4009–4013.
18. [18] Nightingale, J., Woodward, J.M., Guidelines for management of patients with a short bowel. Gut 55:Suppl. (4) (2006), iv1–12.
19. [19] Cusato, J., Allegra, S., De Francia, S., Massano, D., Piga, A., D'Avolio, A., Role of pharmacogenetics on deferasirox AUC and efficacy. Pharmacogenomics 17:6 (2016), 561–572.
20. [20] Brittenham, G.M., Cohen, A.R., McLaren, C.E., Martin, M.B., Griffith, P.M., Nienhuis, A.W., Young, N.S., Allen, C.J., Farrell, D.E., Harris, J.W., Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am. J. Hematol. 42:1 (1993), 81–85.